Invivyd (NASDAQ:IVVD) Reaches New 1-Year High – Time to Buy?

Invivyd, Inc. (NASDAQ:IVVD) hit a new 52-week high during mid-day trading on Saturday . The stock traded as high as $2.76 and last traded at $2.35, with a volume of 136241658 shares trading hands. The stock had previously closed at $1.77.

Analysts Set New Price Targets

Several brokerages recently weighed in on IVVD. Zacks Research raised Invivyd from a “strong sell” rating to a “hold” rating in a research report on Thursday. Weiss Ratings restated a “sell (e+)” rating on shares of Invivyd in a research note on Friday, October 31st. D. Boral Capital raised their price objective on Invivyd from $1.00 to $2.00 and gave the stock a “buy” rating in a report on Monday, October 6th. HC Wainwright lifted their price objective on Invivyd from $5.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Finally, Cantor Fitzgerald assumed coverage on shares of Invivyd in a research report on Monday, October 6th. They set an “overweight” rating and a $10.00 target price for the company. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $6.39.

Invivyd Price Performance

The business has a fifty day moving average of $1.56 and a 200 day moving average of $1.05. The stock has a market cap of $547.83 million, a PE ratio of -5.00 and a beta of 0.63.

Invivyd (NASDAQ:IVVD) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.01). The business had revenue of $13.13 million for the quarter, compared to analysts’ expectations of $12.00 million. Invivyd had a negative return on equity of 92.97% and a negative net margin of 119.63%. On average, equities research analysts expect that Invivyd, Inc. will post -1.64 EPS for the current year.

Insider Transactions at Invivyd

In related news, insider Jill Andersen sold 49,402 shares of the company’s stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $0.57, for a total value of $28,159.14. Following the sale, the insider directly owned 84,446 shares of the company’s stock, valued at $48,134.22. This represents a 36.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold 165,751 shares of company stock valued at $94,478 over the last 90 days. Corporate insiders own 25.40% of the company’s stock.

Institutional Investors Weigh In On Invivyd

Several institutional investors and hedge funds have recently bought and sold shares of the business. XTX Topco Ltd acquired a new stake in shares of Invivyd during the 1st quarter worth approximately $66,000. Vanguard Personalized Indexing Management LLC grew its stake in Invivyd by 238.6% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company’s stock worth $29,000 after buying an additional 28,146 shares during the last quarter. Nuveen LLC acquired a new stake in Invivyd in the first quarter worth $65,000. Squarepoint Ops LLC increased its position in Invivyd by 188.9% in the third quarter. Squarepoint Ops LLC now owns 107,831 shares of the company’s stock worth $119,000 after buying an additional 70,508 shares during the period. Finally, Jefferies Financial Group Inc. bought a new stake in Invivyd in the third quarter valued at $102,000. Institutional investors and hedge funds own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.